| COPD |
FOXO3a/p53 |
+ |
|
Protect against ACEII senescence in rats |
(127) |
| PGC-1α/NF-κB |
+ |
|
Alleviate inflammation and oxidative stress responses |
(33) |
| NF-κB/p65 |
|
+ |
Suppress COPD inflammation |
(66) |
| PGC-1α |
+ |
|
Inhibit oxidative stress and inflammatory response |
(32) |
| Asthma |
IL-6 |
|
+ |
Affect pulmonary function |
(56) |
| mTOR |
+ |
|
Inhibit allergic airway inflammation by suppressing autophagy |
(57) |
| Akt/NF-κB |
|
+ |
Inhibit the development of airway inflammation |
(62) |
| HIF-1α/VEGF |
+ |
|
Increase the secretion of proinflammatory cytokines |
(62) |
| PPAR-γ |
|
+ |
Inhibit anti-inflammatory actions |
(62) |
| Tuberculosis |
TAK1/p65/p38/JNK/ERK |
|
+ |
Enhance the secretion of IL-6 and TNF-α |
(63) |
| RelA/p65 |
|
+ |
Dampen Mtb-mediated persistent inflammatory responses |
(114) |
| GSK3β |
+ |
|
Inhibit M. tuberculosis-induced apoptosis in macrophage |
(58) |
| Bacterial pneumonia |
hBD-2 |
+ |
|
Antimicrobial effect |
(110) |
| IL-8 |
|
+ |
Reduce inflammatory response |
(110) |
| COX-2 |
|
+ |
Reduce the bacterial load in different organs |
(64) |
| Lung cancer |
NF-κB/Smac |
|
+ |
Reduce radiosensitivity |
(59) |
| NF-κB |
|
+ |
Attenuate cell proliferation, migration and invasion |
(67) |
| ATF4 and DDIT4 |
+ |
|
Induce pro-survival autophagy in NSCLC cells |
(82) |
| COVID-19 |
NLRP3 |
|
+ |
Inhibit inflammation |
(70) |
| K63 |
+ |
|
Boost virally mediated induction of type 1 interferons |
(102) |
| HMGB1 |
|
+ |
Enhance the antiviral efficacy of type 1 interferons |
(102) |
| ARDS |
p65 |
|
+ |
Ameliorate inflammatory response and oxidative stress |
(58) |
| MAPK |
|
+ |
Alleviate ARDS |
(132) |
